Astrana Health, Inc. (NASDAQ: ASTH) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 68.60 | EPS (ttm) | 0.52 | Insider Own | 42.71% | Shs Outstand | 49.58M | Perf Week | -6.06% |
| Market Cap | 1.77B | Forward P/E | 19.01 | EPS next Y | 1.88 | Insider Trans | 0.00% | Shs Float | 39.24M | Perf Month | -23.96% |
| Enterprise Value | 2.35B | PEG | 2.32 | EPS next Q | - | Inst Own | - | Short Float | 6.83% | Perf Quarter | 1.97% |
| Income | 25.00M | P/S | 0.73 | EPS this Y | 144.46% | Inst Trans | - | Short Ratio | 4.56 | Perf Half Y | 59.81% |
| Sales | 2.42B | P/B | 3.07 | EPS next Y | 47.61% | ROA | 1.28% | Short Interest | 2.68M | Perf YTD | 43.77% |
| Book/sh | 11.64 | P/C | 3.70 | EPS next 5Y | 29.54% | ROE | 3.88% | 52W High | 51.60 -30.87% | Perf Year | 65.37% |
| Cash/sh | 9.64 | P/FCF | 11.38 | EPS past 3/5Y | -22.55% -14.55% | ROIC | 3.23% | 52W Low | 18.08 97.29% | Perf 3Y | 2.62% |
| Dividend Est. | - | EV/EBITDA | 20.97 | Sales past 3/5Y | 40.63% 53.78% | Gross Margin | 9.31% | Volatility | 3.90% 4.85% | Perf 5Y | -63.28% |
| Dividend TTM | - | EV/Sales | 0.97 | EPS Y/Y TTM | -42.22% | Oper. Margin | 2.45% | ATR (14) | 2.01 | Perf 10Y | 548.55% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | Sales Y/Y TTM | 18.87% | Profit Margin | 0.86% | RSI (14) | 29.33 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | EPS Q/Q | 114.29% | SMA20 | -15.42% | Beta | 0.87 | Target Price | 49.60 |
| Payout | 8.38% | Debt/Eq | 1.92 | Sales Q/Q | 55.65% | SMA50 | -13.63% | Rel Volume | 0.66 | Prev Close | 35.91 |
| Employees | 3,000 | LT Debt/Eq | 1.83 | Earnings | Aug 06 | SMA200 | 17.19% | Avg Volume | 602.41K | Price | 35.67 |
| IPO Date | Mar 11, 2009 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.42% 1.67% | Net Debt/EBITDA | 3.60 | Volume | 397,391 | Change | -0.67% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-14-26 | Reiterated | BTIG | Buy | $40 → $65 |
| May-26-26 | Upgrade | Barclays | Equal Weight → Overweight | $37 → $50 |
| May-14-26 | Reiterated | Truist Securities | Buy | $47 |
| May-11-26 | Reiterated | Barclays | Equal Weight | $26 → $37 |
| May-08-26 | Reiterated | Robert W. Baird | $40 → $45 | |
| May-08-26 | Reiterated | Needham | Buy | $28 → $41 |
| Apr-15-26 | Reiterated | Robert W. Baird | $37 → $40 | |
| Feb-02-26 | Reiterated | BTIG | Buy | $70 → $40 |
| Dec-12-25 | Initiated | Needham | Buy | $28 |
| Nov-25-25 | Reiterated | Jefferies | Buy | $37 |
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating with a physician-centered approach powered by advanced technology. Its operations are structured across three distinct divisions: Care Partners, Care Delivery, and Care Enablement. Astrana Health utilizes its exclusive platform for population health management and healthcare delivery to implement an integrated, value-based care model. This strategic approach empowers the healthcare providers within its network to offer high-quality care to their patients. The organization provides extensive care coordination services to a broad spectrum of stakeholders, including patients, their families, primary care physicians, specialists, acute care hospitals, other inpatient facilities, physician groups, and health plans. Its robust physician network encompasses primary care doctors, specialized practitioners, advanced practice providers (extenders), and hospital-based physicians. Astrana Health serves a diverse patient base, primarily those with insurance coverage—such as private plans, Medicare, Medicaid, and HMOs—but also extends care to uninsured individuals.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,419 | 3,182 | 2,035 | 1,387 | 1,144 | 774 | 370 | 561 | 520 | |
| Cost of Goods Sold Incl. D&A | 2,133 | 2,886 | 1,763 | 1,172 | 945 | 596 | 349 | 468 | 380 | |
| Gross Profit | 285 | 296 | 271 | 215 | 199 | 178 | 22 | 93 | 139 | |
| Selling, General and Administrative Excl. Other | 175 | 217 | 154 | 113 | 78 | 62 | 16 | 41 | 47 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 41 | 0 | 28 | 17 | 17 | 18 | 0 | 19 | 0 | |
| Operating Income | 70 | 79 | 89 | 85 | 104 | 98 | 6 | 32 | 92 | |
| Interest Expense | 31 | 50 | 33 | 16 | 8 | 5 | 3 | 5 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 11 | 25 | 21 | -10 | -15 | 5 | -2 | -9 | |
| Net Income Before Taxes | 52 | 40 | 81 | 90 | 87 | 78 | 9 | 26 | 83 | |
| Income Taxes | 24 | 16 | 31 | 32 | 41 | 32 | 9 | 8 | 22 | |
| Consolidated Net Income | 25 | 22 | 43 | 61 | 45 | 69 | -24 | 14 | 11 | |
| Net Income From Continuing Operations | 27 | 24 | 50 | 58 | 46 | 46 | 0 | 18 | 60 | |
| Net Income | 25 | 22 | 43 | 61 | 45 | 69 | -24 | 14 | 11 | |
| EPS (Recurring) | 0.53 | 0.46 | 0.91 | 1.30 | 1.00 | 1.57 | 1.04 | 0.41 | 0.33 | |
| EPS (Basic, Before Extraordinaries) | 0.53 | 0.46 | 0.91 | 1.30 | 1.00 | 1.57 | 1.04 | 0.41 | 0.33 | |
| EPS (Diluted) | 0.52 | 0.46 | 0.90 | 1.29 | 0.99 | 1.52 | 1.01 | 0.39 | 0.29 | |
| EBITDA | 112 | 135 | 142 | 124 | 112 | 101 | 30 | 49 | 102 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 68.60 | 53.93 | 35.03 | 29.69 | 29.89 | 48.34 | 18.09 | 47.21 | 68.45 | |
| Price To Sales Ratio | 0.72 | 0.38 | 0.74 | 1.30 | 1.16 | 4.18 | 1.83 | 1.15 | 1.26 | |
| Gross Margin | 11.78 | 9.30 | 13.32 | 15.50 | 17.40 | 23.00 | 5.95 | 16.58 | 26.73 | |
| Operating Margin | 2.89 | 2.48 | 4.37 | 6.13 | 9.09 | 12.66 | 1.62 | 5.70 | 17.69 | |
| Net Margin | 1.03 | 0.69 | 2.11 | 4.40 | 3.93 | 8.91 | -6.49 | 2.50 | 2.12 | |
| Shares Outstanding | 49 | 49 | 48 | 47 | 45 | 44 | 37 | 35 | 33 | |
| Market Capitalization | 1,748 | 1,216 | 1,513 | 1,800 | 1,332 | 3,233 | 676 | 644 | 655 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sim Brandon | CEO and President | Feb 02 '26 | Option Exercise | 23.24 | 21,334 | 495,802 | 1,045,329 | Feb 03 |
| Schmidt David | Director | Jan 13 '26 | Option Exercise | 5.79 | 20,000 | 115,800 | 35,763 | Jan 15 |
| Lam Thomas S. | Director | Dec 08 '25 | Option Exercise | 17.78 | 29,502 | 524,546 | 459,122 | Dec 10 |
| Sim Kenneth T. | Executive Chairman | Nov 10 '25 | Option Exercise | 17.78 | 29,502 | 524,546 | 639,407 | Nov 13 |
| Mazdyasni Matthew | Director | Nov 10 '25 | Option Exercise | 18.20 | 20,000 | 364,000 | 34,763 | Nov 12 |
| Kitayama Mitchell W | Director | Nov 07 '25 | Option Exercise | 18.20 | 12,000 | 218,400 | 27,846 | Nov 12 |
| Marsh Linda | Director | Nov 03 '25 | Option Exercise | 18.20 | 20,000 | 364,000 | 103,641 | Nov 05 |
| Kitayama Mitchell W | Director | Sep 15 '25 | Option Exercise | 18.20 | 8,000 | 145,600 | 29,060 | Sep 15 |
| Schmidt David | Director | Sep 02 '25 | Option Exercise | 18.20 | 20,000 | 364,000 | 35,763 | Sep 03 |
| Chiang John | Director | Aug 13 '25 | Option Exercise | 18.20 | 20,000 | 364,000 | 43,132 | Aug 14 |
| Kitayama Mitchell W | Director | Nov 22 '24 | Option Exercise | 18.41 | 3,409 | 62,760 | 21,201 | Nov 26 |
| Chiang John | Director | Nov 19 '24 | Option Exercise | 18.41 | 1,515 | 27,891 | 17,364 | Nov 20 |
| Sim Kenneth T. | Executive Chairman | Nov 18 '24 | Option Exercise | 18.65 | 28,046 | 523,058 | 609,905 | Nov 20 |
| Marsh Linda | Director | Sep 10 '24 | Option Exercise | 15.35 | 11,000 | 168,850 | 80,714 | Sep 12 |
| Kitayama Mitchell W | Director | Sep 10 '24 | Option Exercise | 15.35 | 11,000 | 168,850 | 21,314 | Sep 11 |